Dr Lavinia Spain
Honorary Conjoint Senior Fellow
The Sir Peter MacCallum Department of Oncology
114 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma – The early Australian experience
DOI: 10.1016/j.ejca.2026.1168652026
Journal article
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials
DOI: 10.1016/j.eururo.2026.03.0242026
Journal article
Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.
DOI: 10.1038/s41467-026-74076-y2026
Journal article
Real world outcomes of neoadjuvant immune checkpoint blockade (ICB) for resectable stage III melanoma: Pathologic response and FDG PET/CT correlates.
DOI: 10.1200/jco.2026.44.16_suppl.95692026
Journal article
Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma
DOI: 10.1001/jamanetworkopen.2026.70302026
Journal article
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
DOI: 10.1016/S1470-2045(26)00017-32026
Journal article
Development of a Digital Phenotype for Immune-Related Colitis
DOI: 10.1200/CCI-25-00366
RECENT SCHOLARLY WORKS
2026
Journal article
CYTOSHRINK: A randomized phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with ipilimumab/nivolumab for metastatic kidney cancer.
DOI: 10.1200/JCO.2026.44.7_suppl.4162026
Journal article
Treatment preferences of patients and physicians for early-stage and adjuvant treatment of urothelial carcinoma and renal cell carcinoma in Asia-Pacific: a discrete choice experiment.
DOI: 10.1186/s12894-025-02043-82025
Journal article
Patterns of recurrence after lymphadenectomy for melanoma lymph node metastasis at high risk of recurrence in the modern era of adjuvant systemic therapy.
DOI: 10.1016/j.ejso.2025.111135